the tolerance of a recombinant human interleukin-2 ( ril-2 , r-met hu il-2 [ ala-125 ] , ortho pharmaceutical ) and its antitumor effectiveness in combination with lymphokineactivated killer ( lak ) cells was examined in 26 patients with metastatic solid tumors , including 14 renal cell carcinomas , seven melanomas , three extragonadal germ cell tumors refractory to chemotherapy and two colon carcinomas .
C0218986
recombinant human interleukin-2
C0021756
il-2